Shifts in PEPFAR-supported HIV treatment in 26 countries from 2024 to 2025
Authors:
- Ramona GodboleRGRamona Godbole
- Jonas WachingerJWJonas Wachinger
- Catherine NicholsCNCatherine Nichols
- Marissa CoureyMCMarissa Courey
- Till BärnighausenTBTill Bärnighausen
- Rose MpembeniRMRose Mpembeni
- Frank TanserFTFrank Tanser
- Shannon A. McMahonSMShannon A. McMahon
Open Access
- 24 June 2026
- journal article
- Published by Springer Nature in Nature Health
- Vol. 1 (11) , 1193-1199
Abstract
Here we analysed recently released treatment data from the US President’s Emergency Plan for AIDS Relief (PEPFAR) programme following a year of disruption. Globally ( n = 55 countries), the programme reported approximately 1.97 million (−10.2%) fewer individuals receiving PEPFAR-supported antiretroviral treatment in fiscal year (FY) 2025 as compared with FY2024. FY2025 treatment budget execution declined by approximately 8 percentage points compared with the historical mean. Within a subset of countries selected for further analysis ( n = 26), most experienced absolute declines in PEPFAR-supported treatment and 14 deviated negatively from pre-2025 trends. For South Africa, PEPFAR reported a decline of ∼1.73 million individuals on direct PEPFAR-supported treatment and an increase of ∼1.64 million individuals on treatment benefitting solely from the programme’s broader support to health systems, yielding a net treatment loss of 94,881 (−1.8%) individuals. Outstanding questions remain regarding the drivers, persistence and broader impact of PEPFAR-supported treatment shifts, underscoring the need for timely programme data.Keywords
This publication has 11 references indexed in Scilit:
- PEPFAR interrupted: real-world consequences of U.S foreign aid instability for HIV service delivery in South AfricaThe Lancet Regional Health - Africa, 2026
- HIV Service Delivery Disruptions Following the PEPFAR and USAID HIV Funding Withdrawal in Uganda and Zimbabwe: An Interrupted Time-Series StudySSRN Electronic Journal, 2026
- Fundamental PEPFAR reform risks a period of structural vulnerability in the HIV responseThe Lancet, 2026
- Early impacts of PEPFAR funding freeze on HIV service delivery in mid-Western UgandaBMC Health Services Research, 2026
- Impact of two decades of humanitarian and development assistance and the projected mortality consequences of current defunding to 2030: retrospective evaluation and forecasting analysisThe Lancet Global Health, 2026
- The human cost of US foreign aid cuts: implications for HIV service delivery, research and innovation in South AfricaAIDS Care, 2025
- Evaluating the impact of two decades of USAID interventions and projecting the effects of defunding on mortality up to 2030: a retrospective impact evaluation and forecasting analysisThe Lancet, 2025
- The impact of the PEPFAR funding freeze on HIV deaths and infections: a mathematical modelling study of seven countries in sub-Saharan AfricaeClinicalMedicine, 2025
- Impact of an international HIV funding crisis on HIV infections and mortality in low-income and middle-income countries: a modelling studyThe Lancet HIV, 2025
- By executive order: The likely deadly consequences associated with a 90‐day pause in PEPFAR fundingJournal of the International AIDS Society, 2025